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The objective of the study was to evaluate the efﬁcacy and ease of treatment of an oral
meloxicam suspension for the treatment of chronic musculoskeletal lameness in horses. A
crossover palatability study consisting of 30 healthy horses and ponies was conducted to
compare the time to consume a 400-gram meal of oats alone to a 400-gram meal of oats
top dressed with meloxicam oral suspension (MOS) (0.6 mg/kg body weight [BW]). The
mean time to consume a 400-gram meal of oats only was 301.0  145 seconds and was
286.3  125.6 seconds for MOS. There was no difference between the consumption
duration times of oats with or without MOS. Horses (77) were enrolled into a blinded,
active-controlled, randomized clinical study. Treatment 1 consisted of animals receiving
MOS (0.6 mg/kg BW q24 hours for 5 days), and treatment 2 consisted of animals receiving
phenylbutazone paste (1 g/454 kg BW, q12 hours for 5 days). Animals were treated on day
0 and evaluated for lameness associated with of musculoskeletal disease on day 5. For both
treatments 1 and 2, the day 5 lameness scores were signiﬁcantly less than the day
0 lameness scores. At a walk and trot, there were no differences in efﬁcacy between
phenylbutazone and MOS (based on absolute score values, differences in scores between
day 0 and day 5, and proportion of horses responding to treatment). It was concluded that
MOS was palatable and effective for the treatment of musculoskeletal disease.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction ketoprofen [1–4]. Oral delivery of NSAIDs is preferred overMusculoskeletal disease, which manifests itself as
lameness, remains as the most common ailment of horses.
Themost common treatment for musculoskeletal disease is
nonsteroidal anti-inﬂammatory drugs (NSAIDs) which
include phenylbutazone, meloxicam, ﬂunixin, anda Veterinary Labora-
anada.
).
ier Inc. This is an open accinjection as it is considered safer andmore practical [5]. Top
dressing of feed is also desired as this provides the most
convenient method of delivery of a drug that may require
administration over extended periods of time. Few studies
have evaluated the palatability of top-dressed pharma-
ceutical products in horses [5]; however, this is important
when selecting oral therapeutic products.
Nonsteroidal anti-inﬂammatory drugs act by reduction
in prostaglandin production due to inhibition of the
enzyme cyclooxygenase (COX). The isoenzyme COX-1 isess article under the CC BY-NC-ND license (http://creativecommons.org/
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gastrointestinal and renal homeostasis [1,2]. The COX-2
isoenzyme is expressed in nervous tissue, kidney, bone,
and joints and inhibition reduces pain, inﬂammation, and
fever. Selective COX-2 inhibitors are believed to be beneﬁ-
cial in that they provide therapeutic beneﬁts while main-
taining important homeostatic functions. Many NSAIDs
routinely used in the treatment of musculoskeletal disease
are nonselective COX inhibitors (e.g., phenylbutazone, ﬂu-
nixin) and have well-established negative side effects such
as colitis, gastrointestinal ulceration, and nephrotoxicity
[6–8]. Meloxicam preferentially inhibits the COX-2 isoen-
zyme and has been shown to be safer in foals and adults
horses [9–14].
This study evaluated the efﬁcacy of an oral formulation
of meloxicam [meloxicam oral suspension (MOS)] and
phenylbutazone (Paste) in horses with chronic lameness
associated with musculoskeletal disease. In addition, the
palatability of MOS was evaluated when top dressed to
whole oats. Meloxicam oral suspension (15 mg/mL
meloxicam) has been developed for postsurgical pain and
inﬂammation in cattle and horses (Alberta Veterinary
Laboratories, Calgary Alberta, Canada) [15,16]. Currently,
MOS is registered in Canada for the control of pain and
inﬂammation in cattle undergoing surgical or band
castration.2. Materials and Methods
2.1. Palatability Study
2.1.1. Study Design
The palatability study was a blinded crossover study.
All horses received (1) 400 grams of oats and (2)
400 grams of oats top dressed with MOS at a dose of
0.6 mg per kg body weight (BW). Animals were randomly
allocated to group 1 (oats only for the ﬁrst meal and oats
with meloxicam for the second meal) or group 2 (oats
with meloxicam for the ﬁrst meal and oats only for the
second meal). Oats was offered in a rubber feeding tub to
each animal, and the tub was cleaned between the
crossover periods. The time between the crossover periods
was 2 hours. The duration of time to consume the entire
meal was measured with a stop watch by blinded ob-
servers. The study was reviewed and approved by an
Ethical Care and Use Committee (Alberta Agriculture,
Airdrie). For each horse, the duration times to consume
the entire meal (treatment 1) with and without (treatment
2) MOS were compared using a paired t test.
2.1.2. Animals
Thirty mixed breed, broke horses (26 males and 4 fe-
males) from one riding stable were used in the study. These
included both ponies and full size horses (Quarter horses).
All animals were accustomed to receiving oats as a daily
feed supplement. The horses had not received NSAIDs or
corticosteroids for at least 8 weeks, and all horses were
sound at the time of treatment. Written owner consent was
obtained for use of horses enrolled into the study.2.2. Comparative Efﬁcacy Study
2.2.1. Study Design
This was a blind, active-controlled, randomized clinical
study. Seventy-seven horses were enrolled in the study and
sequentially randomly assigned to either treatment 1,
consisting of animals receiving Meloxicam Oral Suspension
(AVL, Calgary, Alberta, Canada), or treatment 2, animals
receiving phenylbutazone paste (Butequine 1 g/3 mL,
Vetoquinol, Laval Trie, Quebec, Canada). The number of
animals in each treatment group was based on power cal-
culations required to demonstrate noninferiority to phen-
ylbutazone (active control) for clinical improvement of
musculoskeletal disease. The study was conducted ac-
cording to good clinical practice [VICH GL GL9 (GCP) –
GOOD CLINICAL PRACTISE (June 2000)]. The study was
reviewed and approved by an Institutional Ethical Care and
Use Committee.
2.2.2. Animals
Seventy-seven horses (49 geldings and 28 mares) of
mixed breeds ranged in age from 3 to 28 years (15.5  6.0;
mean  standard deviation) and had a history of chronic
lameness for 1 week to 10 years (2.0  2.4 years; mean 
standard deviation) were used in the study. These included
both ponies and full size horses (Quarter Horses). Horses
were selected from private owners in Southern Alberta,
Canada. Horses weighed 136 to 680 kg (506 124 kg; mean
 standard deviation). Written owner consent was ob-
tained for each horse enrolled into the study.
Horses could not have been treated with an NSAID for at
least 14 days or a long lasting corticosteroid for 8 weeks to
be enrolled in the study.
2.2.3. Feed, Water, and Housing
All horses were fed watered and housed based on the
private owners’ speciﬁc facility management practices.
2.2.4. Treatments and Dose Preparation
Treatment 1 consisted of 38 animals receiving MOS at
the dose of 0.6 mg per kg BW q24 hours (1mL per 25 kg BW
every 24 hours) to be delivered as a calculated dose cor-
responding to within 1 kg of actual BW. Animals were
treated once daily for 5 consecutive days (days 0, 1, 2, 3, and
4). Treatment 2 consisted of 39 animals receiving phenyl-
butazone oral paste (1 g/3 mL) at the dose of 1 g/454 kg BW
q12 hours, (3 mL per 454 kg BW every 12 hours) to be
delivered as a calculated dose corresponding to within
1 kg of actual BW. Animals were treated twice daily for 5
consecutive days (days 0, 1, 2, 3, and 4).
The treatment syringes were prepared by the veteri-
nary technician, labeled with study number and animal
identiﬁcation, and provided to the owner with treatment
instructions. The treatment was provided to the owner of
the horse after a clinical examination, and pretreatment
lameness score was recorded and the examining veteri-
narian had left the study site. After the treatment phase,
the syringes were recovered from the owner and weighed
to determine the actual weight and volume of each
treatment.
Table 2
Efﬁcacy score.
Score Description
Overall efﬁcacy score 1 Very gooddexcellent improvement
of clinical condition
2 Gooddmarked improvement of
clinical condition
3 Moderatedonly slight improvement
of clinical condition
4 Poordunchanged or deteriorated
clinical condition
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On day 0, lameness in each limb was scored at standing,
walking, and trotting based on the six-point lameness scale
of the American Association of Equine Practitioners. The
limbwith themost severe lameness was used for scoring in
the study. Lameness at a trot, walk, and rest was assessed
visually before (day 0) and one day after the last treatment
(day 5) by a veterinarian experienced in equine lameness
evaluation. The veterinarian was blinded to the treatments
for the lameness evaluation on days 0 and 5. The scores
were recorded according to the scale described in Table 1.
2.2.6. Overall Efﬁcacy Score
After the lameness examination on day 5, the veterinary
clinician was unblinded and gave each case a summarizing
conclusion on the overall efﬁcacy (scored on a four-point
scale) according to Table 2. A reduction in score of one or
greater was considered a successful outcome to treatment.
2.2.7. Palatability Score
A palatability score was awarded by horse owners at the
time of each treatment according to the following deﬁni-
tion: good (score 1) ¼ horse took treatment willingly,
satisfactory (score 2) ¼ horse took treatment reluctantly,
and poor (score 3) ¼ horse refused to take treatment
willingly. This was entered each day of treatment. A score of
1 was considered a positive palatability score.
2.2.8. BW and Physical Examination
Body weight was determined as part of the general
physical examination conducted on day 0. Body weights
were measured using a portable electronic scale. The day
0 BWs were used to calculate the dosage of the treatments.
2.2.9. Statistical Analysis
The pretreatment and posttreatment lameness scores
were compared using a Wilcoxon signed rank test with a
95% conﬁdence interval. The proportion of animals with
lameness at a stand, walk, and trot were compared using a
Fisher’s exact test with a 95% conﬁdence interval.
Noninferiority and superiority between the test group
(MOS) and the active control group (phenylbutazone) wereTable 1
Lameness scoring system.
Clinical Observation Score Description
Lameness at rest 1 Equal weight bearing on all limbs
2 Weight bearing on affected limb, with
shift of weight to unaffected limb
3 Weight bearing on affected limb only
at tip of hoof
4 No weight bearing on affected limb
Lameness at a
walk and trot
1 Sound or undetectable lameness
2 Barely detectable lameness, lame rarely
or intermittently when turning
3 Mild lameness, mild head bob when
walking or turning
4 Moderate lameness, obvious head bob
at walk, toe pointing frequently
5 Nonweight bearing on affected limb
only at tip of hoof
6 Nonweight bearing 100% of the timeperformed based on the FDA Guidance Document: Active
Controls in Studies to Demonstrate Effectiveness of a New
Animal Drug for Use in Companion Animals (October 2013).
The study was analyzed by calculating from the study data
a two-sided 95% conﬁdence interval where pID is the pro-
portion of cures with the investigational drug and pAC is the
proportion of cures with the active control. The number of
animals in the active control and investigational drug is
represented by nAC and nID, respectively. The upper bound
conﬁdence level (UCL) is determined by the following
calculation:
UCL ¼ ðpAC  pIDÞ þ Zð10:025Þ

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pACð1 pACÞ
nAC
þ pIDð1 pIDÞ
nID
s
If the UCL is less than 0.15 (or 15%), then one can
conclude statistically that the investigational new animal
drug is noninferior. If the upper conﬁdence interval is less
than 0 (negative), then the investigational drug is superior
to the active control.
The overall efﬁcacy and lameness scores assigned by the
clinical veterinarian providing clinical evaluations were
compared using a two-sided Mann–Whitney test with a
95% conﬁdence interval. Palatability scores provided by the
horse owner were compared using a two-sided Mann–
Whitney test with a 95% conﬁdence interval.
3. Results
3.1. Palatability Study
The palatability data are summarized in Table 3. All
horses consumed their entire oat only meal or oats with
MOS meal. There was no signiﬁcant difference between theTable 3
Summary of statistical parameters for palatability study (numbers
represent the combined values of periods 1 and 2 of the crossover).
Variable Oats Only Oats and Meloxicam
Oral Suspension
Number of horses 30 30
Percent of horses consuming meal 100 100
Minimum consumption duration (s) 138.0 165.0
Maximum consumption duration (s) 738.0 642.0
Median consumption duration (s) 245.0 235.5
Mean consumption duration (s) 301.0 286.3
Std. deviation (s) 145.0 125.6
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.6762).
3.2. Musculoskeletal Efﬁcacy Study
The results of the lameness, efﬁcacy, and palatability
scores are summarized in Table 4.
3.2.1. Lameness Evaluation
The number of horses with lameness (score of 2 or
greater) was greatest at a walk and trot, and therefore, the
lameness scores at these activities provided the most
power. For both treatment 1 (MOS) and treatment 2
(phenylbutazone), the day 5 lameness scores were signiﬁ-
cantly less (P < .05) than the day 0 lameness scores which
indicated that both products were effective in treatment of
musculoskeletal disease in horses. At a trot and walk, thereTable 4
Pharmacokinetic parameters following administration of meloxicam oral suspens
and meloxicam treatment groups).
Variable Phenylbutazon
Standing score
Median pretreatment score (day 0) 1
Mean pretreatment score (day 0) 1.15
Median posttreatment score (day 5) 1
Mean posttreatment score (day 5) 1.03
Median difference 0
Mean difference 0.13
Number lame 6
Number positive response 5
Percent responding 83.3
Noninferiority/superiority test UCL ¼ 33.4%, i
Walking score
Median pretreatment score (day 0) 2
Mean pretreatment score (day 0) 1.97
Median posttreatment score (day 5) 1a
Mean posttreatment score (day 5) 1.44a
Median difference 1.97
Mean difference 0.54
Number lame 22
Number positive response 15
Percent responding 68.2
Noninferiority/superiority test UCL ¼ 0.5%,
Trotting score
Median pretreatment score (day 0) 3
Mean pretreatment score (day 0) 3.33
Median posttreatment score (day 5) 2a
Mean posttreatment score (day 5) 2.13a
Median difference 1
Mean difference 1.21
Number lame 39
Number positive response 32
Percent responding 82.1
Noninferiority/superiority test UCL ¼ 8.1%, no
Efﬁcacy score
Total scored 39
% with positive score (1 or 2) 53.8
Median score 2
Mean score 2.38
Palatability score
Total scored 38
% with positive score (1) 42.1
Median score 2
Mean score 1.68
Abbreviation: UCL, upper bound conﬁdence level.
a Signiﬁcantly different from pretreatment score (Mann–Whitney test, P < .05were no differences in efﬁcacy between phenylbutazone
and MOS (based on absolute score values, differences in
scores between day 0 and day 5, and proportion of horses
responding to treatment). Using a noninferiority test, MOS
was both noninferior and superior to the phenylbutazone
active control at awalk and noninferior to the active control
(phenylbutazone) at a trot (Table 4).
3.2.2. Overall Efﬁcacy Score
The assessment of overall efﬁcacy by the veterinarian
performing the examination showed that MOS was signif-
icantly (P < .05) superior to oral phenylbutazone (Table 4).
3.2.3. Owner Palatability Assessment
The assessment of owners demonstrated that MOS was
signiﬁcantly more palatable (P < .05) than phenylbutazone
paste (Table 4).ion to horses (P value represents the comparison between phenylbutazone
e Meloxicam P Value
1 .5268
1.21 .5268
1 1.0000
1.03 1.0000
0 .5061
0.18 .5061
8
6 1.000
75.0 1.000
nsufﬁcient animals for conclusion
2 .9570
1.95 .9570
1a .2583
1.18a .2583
1.95 .2116
0.76 .2116
23
21 .0706
91.3 .0706
noninferior, superior
3 .9474
3.34 .9474
2a .1042
1.92a .1042
1 .1522
1.42 .1522
38
34 .5170
89.5 .5170
ninferior
38
76.3 .0559
2 .0216
2.06 .0216
38
94.7 <.0001
1 <.0001
1.05 <.0001
).
M.E. Olson et al. / Journal of Equine Veterinary Science 44 (2016) 26–31304. Discussion
Meloxicam oral suspension was developed for cattle,
sheep, goats, and horses to control pain and inﬂammation.
The efﬁcacy of MOS for controlling surgical pain and
inﬂammation in horses and cattle has been previously re-
ported [15,16]. It was also developed to treat musculo-
skeletal disease in horses. The product was designed for
easy to delivery by direct oral dosing or top dressed on feed.
These studies were conducted to document efﬁcacy and
palatability in horses.
This study objectively demonstrated the palatability of
MOS. Although few studies have been conducted
measuring palatability of drugs, the authors believe that
measuring consumption times using a familiar feed is the
best way tomeasure palatability. In the horse, consumption
of a meal is driven by pregastric stimulation such as
appearance, taste, odor, and texture [17] and not by pre-
treatment fasting [18]. Horses can completely reject a
medicated feed or have delayed consumption time [5,19].
Horses provided a familiar meal will usually consume the
product, but when the feed has been spiked with an oral
pharmaceutical with an offensive taste, it will be reject
[5,18]. Nonsteroidal anti-inﬂammatory drugs such as
phenylbutazone can cause rejection or delayed feed intake
[3–5,19]. In this study, there was no difference in con-
sumption times of medicated and nonmedicated oats in the
horses. In addition, there was a signiﬁcantly different
palatability score between phenylbutazone paste and MOS
when provided by oral gavage. These studies demonstrate
that MOS is highly palatable.
A blinded, active-controlled, randomized study was
conducted as it can be used to evaluate the efﬁcacy and
address ethical issues regarding not treating animals with a
painful medical condition. Phenylbutazone was selected as
the active control as it is a well-established effective
treatment for musculoskeletal disease throughout the
world [3,4]. The oral paste formulation of phenylbutazone
was used because it is a registered formulationwith a twice
daily dose which is supported by the pharmacokinetics of
oral phenylbutazone [3,5]. The objective of the study and
the development of MOSwas to provide horse owners with
an alternative NSAID that is safer, easier to administer and
more effective product than currently available NSAIDs. The
active ingredient, meloxicam, is a COX-2 selective NSAID
which has been shown to have reduced toxicity to horses
and other mammalian species [9–14]. An oral safety study
was conducted by the authors on 40 horses with MOS ac-
cording to VICH guidelines and was shown to be safe at
doses up to ﬁve times the recommended dose for 15 days
(unpublished results). Other comparative studies using
phenylbutazone as the active control have been conducted
with suxibuzone [20], ﬂunixin [21–23], and ﬁrocoxib [24].
In these studies, there was no difference in efﬁcacy be-
tween the test NSAID and phenylbutazone although there
was certain palatability and/or safety beneﬁts to melox-
icam [9–14]. Similarly, this efﬁcacy study has shown that
MOS was noninferior at treating musculoskeletal lameness
to the nonselective COX inhibitor product, phenylbutazone
paste at a trot, and superior at a walk. There was a sub-
jective belief by the examining veterinarian that MOS wasmore effective than phenylbutazone. The additional bene-
ﬁts of safety and palatability make MOS well suited as an
alternative therapy for phenylbutazone and other NSAIDs,
for the treatment of horses with musculoskeletal disease.
5. Conclusion
Meloxicam oral suspension is highly palatable when top
dressed to feed. It is effective for the treatment of lameness
associated with musculoskeletal disease and as a selective
COX-2 inhibitor, safer for horses than phenylbutazone.
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